Short answer
Axogen, Inc. (AXGN) filed an 8-K current report with the SEC on October 1, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Axogen completed its previously announced acquisition of BioCircuit Technologies on October 1, 2026.
Axogen, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Axogen completed its previously announced acquisition of BioCircuit Technologies on October 1, 2026
- Transaction shifts from announced deal to executed ownership, enabling integration and realization of strategic benefits
- Investors should review Exhibit 99.1 for purchase consideration, financing, and expected financial impact
Item EX-99.1 · Exhibit EX-99.1
- Acquisition of BioCircuit Technologies completed, adding NerveTape™, the first FDA-cleared sutureless peripheral nerve repair device
- BioCircuit expected to contribute approximately $6 million revenue in fourth-quarter 2026 and $34 million in 2027
- Incremental revenue was excluded from Axogen’s full-year 2026 guidance of at least 24% growth, creating potential upside
- Axogen maintains full-year 2026 gross margin guidance of at least 73% and expects to remain free-cash-flow positive
- Strategic fit expands Axogen’s nerve-repair portfolio and leverages its direct sales and hospital contracting infrastructure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Axogen, Inc. 8-K filings
Get the next AXGN 8-K as it lands
Follow AXGN for push alerts, or ask the research agent what this filing means.